Literature DB >> 25696752

Percutaneous septal ablation: a new treatment for hypertrophic obstructive cardiomyopathy.

H Seggewiss.   

Abstract

Entities:  

Year:  2001        PMID： 25696752      PMCID： PMC2499647     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN： 1568-5888            Impact factor:   2.380


× No keyword cloud information.
  10 in total

1.  Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area.

Authors:  L Faber; H Seggewiss; P Ziemssen; U Gleichmann
Journal:  Catheter Cardiovasc Interv       Date:  1999-08       Impact factor: 2.692

2.  Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients.

Authors:  C Knight; A S Kurbaan; H Seggewiss; M Henein; M Gunning; D Harrington; D Fassbender; U Gleichmann; U Sigwart
Journal:  Circulation       Date:  1997-04-15       Impact factor: 29.690

3.  Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.

Authors:  S F Nagueh; N M Lakkis; Z X He; K J Middleton; D Killip; W A Zoghbi; M A Quiñones; R Roberts; M S Verani; N S Kleiman; W H Spencer
Journal:  J Am Coll Cardiol       Date:  1998-07       Impact factor: 24.094

4.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.

Authors:  H Seggewiss; U Gleichmann; L Faber; D Fassbender; H K Schmidt; S Strick
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

5.  Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction.

Authors:  H Seggewiss; L Faber
Journal:  Eur J Echocardiogr       Date:  2000-12

6.  Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss; L Faber; U Gleichmann
Journal:  Thorac Cardiovasc Surg       Date:  1999-04       Impact factor: 1.827

7.  Clinical course of hypertrophic cardiomyopathy in a regional United States cohort.

Authors:  B J Maron; S A Casey; L C Poliac; T E Gohman; A K Almquist; D M Aeppli
Journal:  JAMA       Date:  1999-02-17       Impact factor: 56.272

8.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.

Authors:  U Sigwart
Journal:  Lancet       Date:  1995-07-22       Impact factor: 79.321

9.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography.

Authors:  L Faber; H Seggewiss; U Gleichmann
Journal:  Circulation       Date:  1998-12-01       Impact factor: 29.690

Review 10.  The management of hypertrophic cardiomyopathy.

Authors:  P Spirito; C E Seidman; W J McKenna; B J Maron
Journal:  N Engl J Med       Date:  1997-03-13       Impact factor: 91.245
  10 in total
  1 in total

1.  A case of ventricular asystole without escape rhythm 4 days after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy with drug-resistant paroxysmal atrial fibrillation.

Authors:  Mitsunori Ohtsubo; Hiroto Sakai; Hisashi Kon; Hideyuki Takano
Journal:  J Cardiol Cases       Date:  2011-08-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.